Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Inflammatory Breast Cancer Stage III: early-phase trial registry

1 of 1 indexed Inflammatory Breast Cancer Stage III trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Inflammatory Breast Cancer Stage III: 1 US clinical trial tracked, 1 recruiting.

Inflammatory Breast Cancer Stage III is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Filipa Lynce, MD, running 1 of these trials.

Enrollment posture brief

Registry condition inflammatory-breast-cancer-stage-iii

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Inflammatory Breast Canc (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Inflammatory Breast Cancer Stage III

Inflammatory Breast Cancer Stage III lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Inflammatory Breast Cancer Stage III on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Inflammatory Breast Cancer Stage III is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Filipa Lynce, MD 1 trials

Named interventions

Most-linked intervention names on Inflammatory Breast Cancer Stage III records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Durvalumab Drug
1 trials
Trastuzumab deruxtecan Drug
1 trials

US sites by state

Facility locations filed on Inflammatory Breast Cancer Stage III trials. A trial with sites in several states counts in each.

Texas 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Inflammatory Breast Cancer Stage III page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Inflammatory Breast Cancer Stage III trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Filipa Lynce, MD sponsors the most Inflammatory Breast Cancer Stage III trials on record, review their full trial history before evaluating a specific study. See Filipa Lynce, MD's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Inflammatory Breast Cancer Stage III condition card totals 1 registered trials; most-linked intervention Durvalumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.